Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 iBioLaunch System Achieves Tech Transfer Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News

iBioLaunch System Achieves Tech Transfer Milestone

Can be used by third parties to produce biopharmaceuticals

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

iBio, Inc. has achieved a critical technology transfer milestone verified by an independent third party lab. The validation milestone confirmed that the iBioLaunch system can be used by third parties to replicate production of commercial yields of targeted biopharmaceuticals, including vaccines and therapeutics, without assistance from iBio.
 
“In light of our recently announced commercial collaborations, this is an important demonstration that our technology can be readily utilized by others for commercialization of their respective products,” said Robert Erwin, iBio’s president. “To prove that, we designed the milestone to require the third party lab to implement the iBioLaunch system without assistance from iBio.”
 
The company can also assist with implementing standard operating procedures for the technology and provides quality assurance and quality control documentation and procedures for product and site-specific implementation. iBio also provides staff training in collaboration with the Fraunhofer USA Center for Molecular Biotechnology, which operates a cGMP pilot facility in Delaware based on the iBioLaunch platform.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics